Study of PF-08634404 for early-stage or locally advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have non-small cell lung cancer that is early-stage or locally advanced (stage II or IIIA/B).
- You must have a tumor tissue sample available for testing, either from a previous biopsy or surgery.
- Your cancer's PD-L1 status must be known from local lab results.
- You must be in good enough health to perform daily activities with little to no help (ECOG score 0 or 1).
- You cannot have certain genetic mutations (EGFR or ALK) if you have non-squamous lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This study tests a new medicine called PF-08634404 (an antibody-drug conjugate that targets cancer cells) combined with other anti-cancer drugs in people with advanced non-small cell lung cancer. It aims to see if these combinations are safe and effective. You may be eligible if your cancer has not responded to prior treatments or if you have not received any systemic treatment for advanced disease.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This study tests a new drug called PF-08046033 in people with advanced lung cancer (NSCLC), esophageal cancer (ESCC), or melanoma (skin cancer) that has spread or can't be surgically removed. The drug targets a specific protein to help slow or stop cancer growth.
This trial tests a new combination of an investigational drug (SPGL008) with another therapy (SSGJ-706), with or without chemotherapy, for people with advanced non-small cell lung cancer that has not spread beyond the lungs or has spread to nearby areas. The goal is to see if this combination can help control the cancer.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.